Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing strategies and intelligence.
Market Winning Tool: Traders utilize Benzinga Pro's resources to enhance their trading success in the stock market.
MDT
$98.4+Infinity%1D
Analyst Views on MDT
Wall Street analysts forecast MDT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDT is 110.47 USD with a low forecast of 90.00 USD and a high forecast of 119.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
21 Analyst Rating
Wall Street analysts forecast MDT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDT is 110.47 USD with a low forecast of 90.00 USD and a high forecast of 119.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
11 Hold
0 Sell
Moderate Buy
Current: 97.720
Low
90.00
Averages
110.47
High
119.00
Current: 97.720
Low
90.00
Averages
110.47
High
119.00
Baird
Neutral
downgrade
$109 -> $103
2025-12-16
New
Reason
Baird
Price Target
$109 -> $103
2025-12-16
New
downgrade
Neutral
Reason
Baird lowered the firm's price target on Medtronic to $103 from $109 and keeps a Neutral rating on the shares. The firm adjusted ratings and price targets in medical technology as part of its 2026 outlook. Baird sees "several potential paths to improved" share performance for the group in 2026.
Nephron Research
Hold
to
Buy
upgrade
$120
2025-12-08
Reason
Nephron Research
Price Target
$120
2025-12-08
upgrade
Hold
to
Buy
Reason
Nephron Research upgraded Medtronic to Buy from Hold with a $120 price target. The firm says the company's pickup in growth "has legs."
Barclays
NULL -> Overweight
maintain
$109 -> $111
2025-11-20
Reason
Barclays
Price Target
$109 -> $111
2025-11-20
maintain
NULL -> Overweight
Reason
Barclays raised the firm's price target on Medtronic to $111 from $109 and keeps an Overweight rating on the shares. The firm upped estimates following the company's organic growth "beat and raise" quarter.
Wells Fargo
Overweight
maintain
$100 -> $114
2025-11-19
Reason
Wells Fargo
Price Target
$100 -> $114
2025-11-19
maintain
Overweight
Reason
Wells Fargo raised the firm's price target on Medtronic to $114 from $100 and keeps an Overweight rating on the shares. The firm notes Q2 organic growth of 5.5% exceeded Street, while EPS beat even with the increased opex spend. Medtronic continues to expect a top-line acceleration into the second half of the year and beyond, Wells adds.
About MDT
Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
